While earlier studies of MTSS1 had mainly focused on solid cancers and lymphomas, this is the first study in myeloid neoplasms providing evidence for an important function of MTSS1 as a potential tumor suppressor in AML and as a predictor of clinical outcome. This evidence concerns the gene MTSS1 and acute myeloid leukemia.